Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...

Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML Updated Survival Data From a Pilot Study and Lead-In Phase of...